Naringin reduces body weight, plasma lipids and increases adiponectin levels in patients with dyslipidemia
| Autor: | Teresa Arcelia Garcia-Cobian, Diego Hernandez-Molina, Edy David Rubio-Arellano, Abdel K. Raffoul-Orozco, Jessica Lucia Barajas-Vega, Ernesto Javier Ramírez-Lizardo, Ana E. Ávila-González |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Medicine (miscellaneous) Body weight 01 natural sciences 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Internal medicine Plasma lipids medicine Humans In patient 030212 general & internal medicine Naringin Triglycerides Dyslipidemias Nutrition and Dietetics Adiponectin business.industry Body Weight General Medicine medicine.disease Obesity Lipids 0104 chemical sciences 010404 medicinal & biomolecular chemistry Endocrinology chemistry Flavanones business Dyslipidemia |
| Zdroj: | International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 92(3-4) |
| ISSN: | 0300-9831 |
| Popis: | Abstract. Naringin is a citrus-flavonoid which has been shown to have positive metabolic and anti-inflammatory effects. For this reason, we believe it would be interesting to study the effects of Naringin administration on body weight, BMI, lipid profile and adiponectin levels in patients with dyslipidemia, especially considering that dyslipidemias along with obesity and subsequent cardiometabolic complications are some of the most important public health issues plaguing our society today. A double-blind, randomized clinical trial was conducted in a group of 28 adult patients previously diagnosed with dyslipidemia who attended the Institute of Experimental and Clinical Therapeutics. Patients were divided into two groups; the first group (n = 14) received 450 mg of naringin every 24 hours, in the mornings, while the second group (n = 14) was given a homologated placebo over the course of a 90-day period. Significant differences were observed in naringin group compared to the placebo group in terms of decreased BMI (30.6 ± 3.19 vs 33.3 ± 3.23 kg/m2; p = 0.03), total cholesterol (182 ± 20.2 vs 245 ± 24.1 mg/dl; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|